文献速递结核与非结核分枝杆菌

世界卫生组织结核病诊断目标产品概况评估指南:世卫组织流程与研究设计原则介绍

Guidance for the Evaluation of Tuberculosis Diagnostics That Meet the World Health Organization (WHO) Target Product Profiles: An Introduction to WHO Process and Study Design Principles.
PubMed 文献 · J Infect Dis · 2019-01-01

本文介绍世界卫生组织(WHO)关于评估符合4个高优先级结核病诊断目标产品概况(TPP)的检测方法的指南系列。该系列旨在为新型诊断产品准确性研究提供设计指导,以生成充分证据支持WHO证据审查流程并加速政策制定。本文概述了系列目的、WHO证据需求与政策指南制定流程,以及诊断研究设计的关键考虑因素。

要点

  • WHO高优先级TPP明确了结核病诊断开发的重要需求,准确性研究是验证所有检测的基础步骤。
  • 诊断准确性研究常在设计、执行和报告方面存在局限,导致证据确定性低,可能延迟或阻碍政策与推广决策。
  • 研究设计需考虑预期用途、临床路径角色、人群与场所选择、参考标准与对照、研究流程与标本问题及准确性之外的关键问题。

核心结论

  • 本指南系列旨在为符合WHO高优先级TPP的新型结核病诊断产品准确性研究提供设计指导,以支持协调的证据生成和WHO审查流程。

研究设计与样本

  • 本文为指南系列介绍性文章,概述了研究指导的目的、WHO证据需求与政策制定流程,以及诊断研究设计的一般考虑因素。

主要发现

  • 诊断准确性研究设计、执行和报告的局限性可导致真实检测性能证据确定性低,延迟或阻碍政策与推广决策。
  • 研究设计考虑包括预期用途与临床路径角色、人群与场所选择、指标检测特定问题、参考标准与对照、研究流程与标本问题及准确性之外的关键问题。

关键数值与推荐

  • WHO现有高优先级TPP确立了结核病诊断开发的重要需求;本系列后续4篇文章将分别为4个WHO高优先级TPP提供详细指导。

临床怎么用

  • 开展新型结核病诊断产品准确性研究时,应参考本指南的设计原则,以确保生成足以支持WHO证据审查的高质量证据。

局限性

  • 本文为介绍性文章,未报告具体研究数据或系统评价结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Existing high-priority target product profiles (TPPs) of the World Health Organization (WHO) establish important needs for tuberculosis (TB) diagnostic development. Building on this earlier work, this guidance series aims to provide study guidance for performing accuracy studies of novel diagnostic products that may meet the 4 high-priority WHO TPPs and thus enable adequate evidence generation to inform a WHO evidence review process. Diagnostic accuracy studies represent a fundamental step in the validation of all tests. Unfortunately, such studies often have limitations in design, execution, and reporting, leading to low certainty of the evidence about true test performance, which can delay or impede policy and scale-up decisions. This introductory paper outlines the following: (1) the purpose of this series of papers on study guidance; (2) WHO evidence needs and process for the development of policy guidelines for new TB diagnostic tests; and (3) study design considerations, ie, general diagnostic study considerations, intended use of test and role in the clinical pathway, choice of population and setting, index-test specific issues, suitable reference standard and comparators, study flow and specimen issues, and finally key issues beyond accuracy that should be considered. The other 4 papers in this series will provide more detailed guidance for each of the 4 WHO high-priority TPPs. By increasing the clarity around the clinical evaluation needs for tests that have the potential to meet the TPP specifications, we hope to support harmonized evidence generation and enable the WHO review process towards meeting the WHO End TB Strategy targets for reducing the incidence and mortality associated with TB.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Denkinger CM, Schumacher SG, Gilpin C, et al. Guidance for the Evaluation of Tuberculosis Diagnostics That Meet the World Health Organization (WHO) Target Product Profiles: An Introduction to WHO Process and Study Design Principles. J Infect Dis. 2019. PMID: 31593596. doi:10.1093/infdis/jiz097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。